Research Article
Lactate Arterial-Central Venous Gradient among COVID-19 Patients in ICU: A Potential Tool in the Clinical Practice
Table 1
Baseline characteristics on ICU admission and ICU outcomes of the enrolled population.
| Variable | Median (IQR) |
| Age (years) | 66.0 (55.0–71.0) | Charlson comorbidity index | 2.0 (1.0–3.0) | SAPS II score | 37.0 (29.0–41.5) | Brixia score | 10.0 (9.0–11.5) | Interleukin-6 (pg/mL) | 40.3 (10.0–759.5) | Alanine aminotransferase (U/L) | 32.0 (20.5–83.5) | Creatinine (mg/dL) | 0.75 (0.58–0.87) | PaO2/FiO2 ratio | 195.0 (152.5–219.5) | PaCO2 (mmHg) | 51.7 (41.6–55.6) | Arterial lactate (mmol/L) | 1.65 (0.96–2.07) | Central venous lactate (mmol/L) | 1.44 (0.76–1.84) | Delta a-cv lactate (mmol/L) | 0.15 (0.07–0.25) | Length of mechanical ventilation (days) | 19.0 (10.0–42.0) | Length of stay in ICU (days) | 22.0 (12.50–49.50) | Survival rate at ICU discharge (n; %) | 16; 76.2% |
|
|
ICU: intensive care unit; IQR: interquartile range; SAPS II: Simplified Acute Physiology Score; a-cv: arterial-central venous.
|